Pharma Focus Asia

ImaginAb announces extension of long-standing partnership with Boehringer Ingelheim

Monday, July 26, 2021

ImaginAb Inc, a market leading global biotechnology company, focused on developing next generation immuno oncology imaging agents and therapeutic radiopharmaceuticals (RPT), today announced the signing of a new significant multi-year, non-exclusive license agreement with Boehringer Ingelheim.

The agreement, which builds on the long-term collaboration between the two companies that started in 2017 will see ImaginAb supply clinical doses of its market leading 89Zr CD8 ImmunoPET technology to Boehringer Ingelheim for use in the clinical development of its novel oncology therapeutics throughout North America and Europe.

ImaginAb will receive license fees and payments for providing ongoing technical, clinical, and regulatory support to enable the successful implementation of its CD8 ImmunoPET technology. No other terms were disclosed.

Commenting on the announcement, Ian Wilson, Chief Executive Officer of ImaginAb stated:

“Boehringer Ingelheim, were the first to partner with us on our CD8 ImmunoPET agent, and we are delighted we can expand our partnership and enable our technology to be used across multiple clinical programs “

Wilson continued “ImaginAb has a clear aim to become the lead in diagnostic and treatment choices, transforming patient care and helping patients live better and healthier lives. Our CD8 ImmunoPET technology enables quicker identification of drug efficacy, potentially reduce the length of trials and allowing new therapies to advance to market quicker. It also removes the need for repeat, painful biopsies. All of which will ultimately transform patient care.

This announcement is just the latest in a number of new non-exclusive license agreements that we have announced this year. It is a clear indication that not only is our technology gaining wider acceptance, but many others also share our vision, and belief in the benefits that our CD8 ImmunoPET technology offers”.

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024